News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,482 Results
Type
Article (214)
Company Profile (1)
Press Release (1267)
Section
Business (525)
Career Advice (1)
Deals (42)
Drug Delivery (1)
Drug Development (346)
FDA (25)
Job Trends (29)
News (908)
Policy (45)
Tag
Academia (1)
Alliances (84)
Antibody-drug conjugate (ADC) (1)
Approvals (27)
Artificial intelligence (7)
Best Places to Work (19)
Biosimilars (1)
Biotechnology (1)
Bladder cancer (1)
Breast cancer (1)
Cancer (27)
Career advice (1)
Clinical research (303)
Collaboration (4)
COVID-19 (7)
C-suite (4)
Data (11)
Denatured (3)
Diagnostics (1)
Drug discovery (1)
Drug pricing (1)
Earnings (233)
Events (321)
Executive appointments (2)
FDA (31)
Funding (1)
Generative AI (1)
Gene therapy (1)
GLP-1 (1)
Government (7)
Guidances (2)
Healthcare (14)
Immuno-oncology (1)
Infectious disease (7)
IPO (18)
Job creations (10)
Job search strategy (1)
Kidney cancer (4)
Layoffs (3)
Legal (6)
Liver cancer (1)
Lung cancer (3)
Lymphoma (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (26)
Neurodegenerative disease (1)
Neuroscience (1)
NextGen: Class of 2026 (5)
Non-profit (2)
Opinion (6)
Pancreatic cancer (1)
Patents (1)
People (225)
Phase I (117)
Phase II (94)
Phase III (154)
Pipeline (8)
Postmarket research (2)
Preclinical (19)
Prostate cancer (3)
Real estate (5)
Regulatory (45)
Research institute (2)
Series B (1)
Special edition (1)
Startups (1)
The Weekly (1)
Date
Today (2)
Last 7 days (4)
Last 30 days (8)
Last 365 days (63)
2026 (7)
2025 (63)
2024 (66)
2023 (101)
2022 (118)
2021 (118)
2020 (96)
2019 (64)
2018 (70)
2017 (92)
2016 (81)
2015 (68)
2014 (50)
2013 (36)
2012 (53)
2011 (66)
2010 (49)
Location
Africa (4)
Asia (40)
Australia (6)
California (51)
Canada (1)
China (2)
Connecticut (1)
Europe (178)
Maryland (1)
Massachusetts (3)
New Jersey (1)
New York (2)
Northern California (32)
Pennsylvania (1)
South America (4)
Southern California (12)
Texas (1)
United States (62)
Washington State (1)
Wisconsin (1)
1,482 Results for "exelixis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Exelixis Lays Off 130 as Pennsylvania Site Closes Down
Exelixis is looking at the possibility of relocating some of the eliminated Pennsylvania roles to its headquarters in Alameda, California, according to a company spokesperson.
August 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
January 28, 2026
·
1 min read
Press Releases
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
January 7, 2026
·
1 min read
Press Releases
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 8, 2026
·
10 min read
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
January 12, 2026
·
19 min read
Press Releases
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
December 4, 2025
·
1 min read
Press Releases
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November 2025
November 6, 2025
·
1 min read
Press Releases
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 4, 2025
·
19 min read
1 of 149
Next
